Assessment of clinical benefit, cost and uptake of biosimilars versus reference biologics in immune-mediated inflammatory diseases in China
2024

Comparing Biosimilars and Reference Biologics for Inflammatory Diseases in China

Sample size: 5717 publication 10 minutes Evidence: high

Author Information

Author(s): Du Xin, Luo Xingxian, Guo Qixiang, Jiang Xiaomeng, Su Ziling, Zhou Weiting, Wang Zhongjian, Li Jiarun, Yang Yue, Zhang Yi

Primary Institution: Vanke School of Public Health, Tsinghua University, Beijing, China

Hypothesis

This study aims to assess the clinical benefits, cost, and uptake of biosimilars compared to reference biologics in patients with immune-mediated inflammatory diseases in China.

Conclusion

IMID biosimilars in China provide clinical benefits comparable to their reference biologics and offer significant cost savings.

Supporting Evidence

  • Biosimilars demonstrated comparable safety and efficacy to reference biologics in multiple studies.
  • Patients using biosimilars could save between $874 and $2,184 per month.
  • Uptake rates for biosimilars ranged from 16.5% to 72.1% in China.
  • Simulation showed significant potential savings with 100% biosimilar substitution.

Takeaway

Biosimilars are cheaper versions of expensive drugs that work just as well, helping more people get the treatment they need.

Methodology

The study analyzed 12 RCTs and cohort studies comparing biosimilars to reference drugs, assessing efficacy, safety, and cost.

Potential Biases

Some studies had uncertain risk of bias, and the absence of real-world data may affect the findings.

Limitations

The study's generalizability is limited due to the lack of real-world evidence from China and reliance on published data.

Participant Demographics

The study included a total of 5,717 patients with IMIDs, with varying demographics across the included studies.

Statistical Information

P-Value

0.33

Confidence Interval

95% CrI, 0.99–1.06

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3389/fpubh.2024.1476213

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication